Revivent TC System
Phase 3- Indications
- Heart failure, Ischemic heart failure, Heart failure with reduced ejection fraction
Company intelligence / Profile preview
BioVentrix, Inc.
San Ramon, California, United Statesbioventrix.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
The company's Revivent TC System has received CE Mark in Europe and is pending FDA approval in the US. In 2023, the FDA granted an expanded access program allowing ongoing usage of the implants in high-risk patients with heart failure. The company is conducting the REVIVE-HF clinical trial in Europe, comparing the Revivent TC System to Guideline-Directed Medical Therapy.
- Therapeutic areas
- Cardiovascular
- Modalities
- Transcatheter devicesinjectable hydrogel
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on BioVentrix, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioVentrix, Inc..